Perrigo announced that it has received final approval from the FDA to launch Morphine Sulfate Oral Solution.
Morphine Sulfate Oral Solution, a Schedule II controlled substance, is indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. In general, opioid analgesics act primarily at the mu-receptors. Higher dosages, however, may result in activity at the other receptor subtypes.
Morphine Sulfate Oral Solution will be available in a 100mg/5mL dosage strength.
For more information call (800) 719-9260 or visit www.perrigo.com.